Cargando…

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyung Soon, Kwon, Woo Sun, Park, Sejung, Jo, Eunji, Lim, So Jung, Lee, Choong-kun, Lee, Jii Bum, Jung, Minkyu, Kim, Hyo Song, Beom, Seung-Hoon, Park, Jun Yong, Kim, Tae Soo, Chung, Hyun Cheol, Rha, Sun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805480/
https://www.ncbi.nlm.nih.gov/pubmed/31639056
http://dx.doi.org/10.1186/s40425-019-0708-8
_version_ 1783461394816958464
author Park, Hyung Soon
Kwon, Woo Sun
Park, Sejung
Jo, Eunji
Lim, So Jung
Lee, Choong-kun
Lee, Jii Bum
Jung, Minkyu
Kim, Hyo Song
Beom, Seung-Hoon
Park, Jun Yong
Kim, Tae Soo
Chung, Hyun Cheol
Rha, Sun Young
author_facet Park, Hyung Soon
Kwon, Woo Sun
Park, Sejung
Jo, Eunji
Lim, So Jung
Lee, Choong-kun
Lee, Jii Bum
Jung, Minkyu
Kim, Hyo Song
Beom, Seung-Hoon
Park, Jun Yong
Kim, Tae Soo
Chung, Hyun Cheol
Rha, Sun Young
author_sort Park, Hyung Soon
collection PubMed
description BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). RESULTS: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. CONCLUSIONS: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0708-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6805480
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68054802019-10-24 Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer Park, Hyung Soon Kwon, Woo Sun Park, Sejung Jo, Eunji Lim, So Jung Lee, Choong-kun Lee, Jii Bum Jung, Minkyu Kim, Hyo Song Beom, Seung-Hoon Park, Jun Yong Kim, Tae Soo Chung, Hyun Cheol Rha, Sun Young J Immunother Cancer Research Article BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). RESULTS: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. CONCLUSIONS: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0708-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-10-21 /pmc/articles/PMC6805480/ /pubmed/31639056 http://dx.doi.org/10.1186/s40425-019-0708-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Park, Hyung Soon
Kwon, Woo Sun
Park, Sejung
Jo, Eunji
Lim, So Jung
Lee, Choong-kun
Lee, Jii Bum
Jung, Minkyu
Kim, Hyo Song
Beom, Seung-Hoon
Park, Jun Yong
Kim, Tae Soo
Chung, Hyun Cheol
Rha, Sun Young
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title_full Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title_fullStr Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title_full_unstemmed Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title_short Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
title_sort comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805480/
https://www.ncbi.nlm.nih.gov/pubmed/31639056
http://dx.doi.org/10.1186/s40425-019-0708-8
work_keys_str_mv AT parkhyungsoon comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT kwonwoosun comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT parksejung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT joeunji comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT limsojung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT leechoongkun comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT leejiibum comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT jungminkyu comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT kimhyosong comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT beomseunghoon comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT parkjunyong comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT kimtaesoo comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT chunghyuncheol comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer
AT rhasunyoung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer